Target‐mediated drug disposition modeling of an anti‐TFPI antibody (MG1113) in cynomolgus monkeys to predict human pharmacokinetics and pharmacodynamics

Background MG1113 is a human monoclonal antibody of tissue factor pathway inhibitor (TFPI) under development for prophylaxis for hemophilia patients with or without inhibitors against factor VIII products, which have been used for the treatment of hemophilia. Because TFPI is a negative regulator in...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of thrombosis and haemostasis 2021-06, Vol.19 (6), p.1425-1435
Hauptverfasser:	Kwak, Eun‐young, Kim, Min ju, Park, Jin hyun, Jung, Ha wook, Jung, Myung Eun
Format:	Artikel
Sprache:	eng
Schlagworte:	Clinical trials Coagulation Coagulation factors Dosage Drug dosages Hemophilia human dose prediction Intravenous administration Monoclonal antibodies monoclonal antibody non‐linear pharmacokinetics Pharmacodynamics Pharmacokinetics Prophylaxis TFPI Tissue factor TMDD
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!